Free Trial

Doximity, Inc. (NASDAQ:DOCS) Holdings Decreased by Baillie Gifford & Co.

Doximity logo with Medical background

Baillie Gifford & Co. reduced its position in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 9.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,359,235 shares of the company's stock after selling 537,291 shares during the period. Baillie Gifford & Co. owned 2.89% of Doximity worth $233,502,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Janney Montgomery Scott LLC boosted its position in shares of Doximity by 17.4% in the first quarter. Janney Montgomery Scott LLC now owns 20,802 shares of the company's stock worth $560,000 after acquiring an additional 3,086 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of Doximity by 40.1% during the first quarter. GSA Capital Partners LLP now owns 17,390 shares of the company's stock valued at $468,000 after purchasing an additional 4,981 shares during the period. Texas Permanent School Fund Corp raised its stake in shares of Doximity by 4.9% during the first quarter. Texas Permanent School Fund Corp now owns 106,915 shares of the company's stock valued at $2,877,000 after purchasing an additional 5,018 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Doximity by 18.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 15,320 shares of the company's stock valued at $412,000 after purchasing an additional 2,432 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Doximity by 36.5% during the first quarter. Sei Investments Co. now owns 35,010 shares of the company's stock valued at $942,000 after purchasing an additional 9,359 shares during the period. 87.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DOCS has been the topic of a number of analyst reports. Barclays lifted their price objective on shares of Doximity from $52.00 to $75.00 and gave the company an "overweight" rating in a research note on Monday. Morgan Stanley lifted their price objective on shares of Doximity from $26.00 to $33.00 and gave the company an "underweight" rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. lifted their price objective on shares of Doximity from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Monday, August 19th. Raymond James restated an "outperform" rating and issued a $65.00 price target (up previously from $37.00) on shares of Doximity in a research note on Friday. Finally, Evercore ISI lifted their price target on shares of Doximity from $34.00 to $45.00 and gave the stock an "in-line" rating in a research note on Tuesday, October 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $45.69.

Check Out Our Latest Research Report on DOCS

Doximity Stock Performance

Shares of DOCS traded down $2.40 during midday trading on Tuesday, hitting $58.85. 2,343,372 shares of the stock traded hands, compared to its average volume of 1,713,546. Doximity, Inc. has a 1-year low of $22.96 and a 1-year high of $61.75. The firm has a market capitalization of $10.93 billion, a PE ratio of 70.40, a price-to-earnings-growth ratio of 7.00 and a beta of 1.30. The business's 50 day moving average price is $42.04 and its two-hundred day moving average price is $33.44.

Doximity Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Further Reading

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Should you invest $1,000 in Doximity right now?

Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines